ASH 2015 – Multiple Myeloma

A phase 1, multicenter study evaluated the use of PvD in patients with proteasome inhibitor–exposed and lenalidomide-refractory multiple myeloma to examine the maximum tolerated dose with secondary end points of safety, overall response rate, duration of response, and time to response. Read More ›

Read More ›

Read More ›

The VISTA study demonstrated good tolerability of VMP; however, in a subsequent phase 2 trial, there was a higher rate of treatment discontinuation than expected. In this study, investigators demonstrated lowering the intensity of VMP proved to be both safe and effective for newly diagnosed multiple myeloma (NDMM). Read More ›

Researchers present the final data for the secondary end point of overall survival across the entire study population of the phase 3 clinical trial PANORAMA 1, which evaluated panobinostat in combination with bortezomib and dexamethasone. Overall survival was not statistically significant. Read More ›

Read More ›

This phase 3 study demonstrated that the all-oral therapy of ixazomib in combination with lenalidomide/dexamethasone significantly increased median PFS without a substantial increase in overall toxicity. A similar benefit was noted in patients with high-risk cytogenetics. Read More ›

Read More ›

A pharmacokinetic and safety study of ixazomib in patients with severe renal impairment or end-stage renal disease requiring hemodialysis demonstrated that this patient subgroup requires dose modification of ixazomib due to a 38% higher, unbound systemic exposure. Administration of ixazomib may be administered without regard to the timing of dialysis. Read More ›

Read More ›